Apolipoprotein D (ApoD) In Human Serum As Marker Of Parkinson's Disease
NCT ID: NCT01467960
Last Updated: 2013-10-30
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
180 participants
OBSERVATIONAL
2011-11-30
2013-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To achieve this goal, Apolipoprotein D (ApoD) in human serum as a marker of the oxidative stress-inflammation vicious cycle seems most promising candidate for diagnosis.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study Part 1:
Health persons: n=90; Groups of health persons: n=3; Subjects per group: n=30.
Study Part 2:
Patients: n=90; Groups of patients: n=3; Subjects per group: n=30.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group I
Healthy Subjects aged 20-40
No interventions assigned to this group
Group II
Healthy Subjects aged 40-65
No interventions assigned to this group
Group III
Healthy Subjects aged more than 65
No interventions assigned to this group
Group A
Patients at Stage I, H\&Y classification
No interventions assigned to this group
Group B
Patients at Stage II, H\&Y classification
No interventions assigned to this group
Group C
Patients at Stage more than III, H\&Y classification
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Persons \> 20 years
Exclusion Criteria
* Patients, who are post-ictus and/or traumatic brain injury (TBI)
* Patients, who are treated with antipsychotic drugs
* Obese persons (BMI \> 27)
* Idiopathic normal pressure idrocephalus (INPI)
* Paget's disease
* Breast cancer
* Adenocarcinoma of the prostate
* Glucose-6-phosphate (GSD-I) deficiency
* Insuline-resistance-related disorders
20 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Privatklinik Villa Melitta
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Andreas Waldner
Study Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andreas Waldner, MD
Role: STUDY_DIRECTOR
Privatklinik Villa Melitta
Sarah Dassati, BSc
Role: PRINCIPAL_INVESTIGATOR
Privatklinik Villa Melitta
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Privatklinik Villa Melitta
Bolzano, Südtirol, Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bennett MD. The time and duration of meiosis. Philos Trans R Soc Lond B Biol Sci. 1977 Mar 21;277(955):201-26. doi: 10.1098/rstb.1977.0012.
Patterson D, Carnright DV. Biochemical genetic analysis of pyrimidine biosynthesis in mammalian cells: I. Isolation of a mutant defective in the early steps of de novo pyrimidine synthesis. Somatic Cell Genet. 1977 Sep;3(5):483-95. doi: 10.1007/BF01539120.
Arnesen K, Nordstoga K. Ocular encephalitozoonosis (nosematosis) in blue foxes. Polyarteritis nodosa and cataract. Acta Ophthalmol (Copenh). 1977 Aug;55(4):641-51. doi: 10.1111/j.1755-3768.1977.tb05662.x.
Weidler DJ, Sieck GC. A study of ion binding in the hemolymph of Periplaneta americana. Comp Biochem Physiol A Comp Physiol. 1977;56(1A):11-4. doi: 10.1016/0300-9629(77)90433-9. No abstract available.
Bergdahl B, Andersson KE. Stability in vitro of methylproscillaridin. Eur J Clin Pharmacol. 1977 Apr 20;11(4):267-71. doi: 10.1007/BF00607675.
Kovatsis A, Kovatsi-Kotsaki V, Elezoglou B, Kounenis G. Physiological antagonism between PGE2, PGA1, PGF1-alpha and NADP, beta-NAD on isolated rabbit jejunum. Arzneimittelforschung. 1976;26(11):1997-9.
Shankar GM, Walsh DM. Alzheimer's disease: synaptic dysfunction and Abeta. Mol Neurodegener. 2009 Nov 23;4:48. doi: 10.1186/1750-1326-4-48.
Dalmark M. Chloride in the human erythrocyte: distribution and transport between cellular and extracellular fluids and structural features of the cell membrane. Prog Biophys Mol Biol. 1976;31(2):145-64. No abstract available.
Miller J, Wallace D, Grieco MH, Frenkel R, Larsen K. Double-blind trial of oral carbuterol in bronchial asthma. Ann Allergy. 1977 Jul;39(1):12-7.
Fall RR. Stabilization of an acetyl-coenzyme A carboxylase complex from Pseudomonas citronellolis. Biochim Biophys Acta. 1976 Dec 20;450(3):475-80. doi: 10.1016/0005-2760(76)90022-9.
Hong JS. An ecf mutation in Escherichia coli pleiotropically affecting energy coupling in active transport but not generation or maintenance of membrane potential. J Biol Chem. 1977 Dec 10;252(23):8582-8. No abstract available.
Kricka LJ, Carter TJ. A method for enhancing the stability of thiol-containing enzymes immobilised on nylon. Clin Chim Acta. 1977 Aug 15;79(1):141-7. doi: 10.1016/0009-8981(77)90471-5.
Related Links
Access external resources that provide additional context or updates about the study.
Participating Centre for ApoD Detection
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Melitta-ApoD-2011
Identifier Type: -
Identifier Source: org_study_id